ANGES

anges-logo

AnGes MG, Inc. is a biopharmaceutical company with a mission to provide patients, especially those suffering from disease for which no effective therapy has been available to date, with innovative drugs. AnGes focuses on development of gene medicine, a next-generation biopharmaceutical. AnGes MG, Inc. was founded in December 1999 on an innovative discovery by researchers at Osaka University. AnGes already went through the first stage of research and development and is now in the second stage ... of commercialization. “Naglazyme®,” a drug for the treatment of mucopolysaccharidosis VI, an intractable disease, has already been marketed in Japan and HGF Plasmid (gene therapy) for the treatment of critical limb ischemia, which is a serious impairment of blood circulation in the legs, is in the last stage of clinical development. Development of “NF-κB decoy oligonucleotide,” a nucleic acid medicine that suppresses various types of inflammation including atopic dermatitis, disc degeneration, and medical device for prevention of vascular restenosis is also under way. Having started from research and development and now embarking on the new stage of practical application, AnGes strives to fulfill the expectations of patients, their families, shareholders, investors and the general public waiting for new drugs to be available and aims at becoming a “global leader in the field of gene medicine.”

#SimilarOrganizations #People #Financial #Website #More

ANGES

Social Links:

Industry:
Biopharma Biotechnology Genetics Health Care

Founded:
1999-01-01

Address:
Tokyo, Tokyo, Japan

Country:
Japan

Website Url:
http://www.anges.co.jp

Total Employee:
51+

Status:
Active

Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro SPF Apple Mobile Web Clips Icon Google Tag Manager Google Analytics Amazon SSL By Default Global Site Tag


Similar Organizations

enzyvant-sciences-logo

Enzyvant Sciences

Enzyvant Sciences is a biotechnology company which focuses on developing treatments for rare diseases.

mast-therapeutics-logo

Mast Therapeutics

Mast Therapeutics is a biopharmaceutical company developing novel, clinical-stage therapies for serious or life-threatening diseases.

soligenix-logo

Soligenix

Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.

watsin-logo

Watsin

Watsin is a high-tech biopharmaceutical company engaged in the R&D of gene engineering medicine.


Current Advisors List

not_available_image

Kunio Iwatani Outside Directors @ AnGes
Board_member

Current Employees Featured

not_available_image

EI Yamada
EI Yamada President & CEO @ AnGes
President & CEO
2001-05-01

andy-g-hinson_image

Andy G. Hinson
Andy G. Hinson Senior Director of Clinical Development @ AnGes
Senior Director of Clinical Development

Stock Details


Company's stock symbol is TYO:4563

Acquisitions List

Date Company Article Price
2020-12-15 EmendoBio, Inc. EmendoBio, Inc. acquired by AnGes 250 M USD

Investors List

biofrontier-partners_image

Biofrontier Partners

Biofrontier Partners investment in Seed Round - AnGes

Investments List

Date Company Article Money raised
2020-12-15 EmendoBio, Inc. AnGes investment in Corporate Round - EmendoBio, Inc. 250 M USD
2020-01-15 EmendoBio, Inc. AnGes investment in Series B - EmendoBio, Inc. 61 M USD
2018-08-15 MyBiotics Pharma LTD AnGes investment in Series A - MyBiotics Pharma LTD 8 M USD
2015-04-10 FunPep AnGes investment in Venture Round - FunPep 25.6 M JPY
2005-08-12 Dolthera GmbH AnGes investment in Series B - Dolthera GmbH 14.5 M EUR

Official Site Inspections

http://www.anges.co.jp Semrush global rank: 2.07 M Semrush visits lastest month: 9.9 K

Unable to get host informations!!!

Loading ...

More informations about "AnGes"

AnGes, Inc.

AnGes , Inc. is a biopharmaceutical company with the mission of providing patients suffering from diseases for which no effective therapy has been available to date, with innovative drugs. …See details»

アンジェス - Wikipedia

アンジェス株式会社 は、 遺伝子医薬 開発を行う日本のバイオ製薬企業。そのファイナンスの姿勢から、株券印刷業者とも呼ばれている [1][2]。See details»

AnGes - Crunchbase Company Profile & Funding

AnGes is a biopharmaceutical company specialized in HGF plasmid, NFkB decoy oligonucleotide, and therapeutic vaccines.See details»

AnGes - businessabc

Feb 18, 2025 AnGes was founded in 2000 in Tokyo, Japan. The company has since gone on to become one of the largest and most respected biotech companies in the country. AnGes has …See details»

【アンジェス】 [4563]企業概要 社員数や役員報酬・資本金 | 日経 …

【日本経済新聞】アンジェス [4563]の企業概要。役員人事や社員数、資本金に関する情報から関連会社や取引先、監査法人などあらゆる知りたい ...See details»

AnGes Company Profile - Office Locations, Competitors, Revenue …

Oct 29, 2024 AnGes has 5 employees across 6 locations and ¥152.98 m in annual revenue in FY 2023. See insights on AnGes including office locations, competitors, revenue, financials, …See details»

企業調査 - 株式会社フィスコ

になることを目指している。新薬候補品を開発し、販売パートナーとの販売権許諾契約によって得られる契約一時金や、開発の進捗状況等によって得られるマイルストーン収入、上市後の …See details»

AnGes Company Profile | Management and Employees List

May 20, 2014 AnGes Profile and History AnGes, Inc., a biopharmaceutical company, engages in the research and development of gene-based medical products. Its lead product is Hepatocyte …See details»

AnGes, Inc. | Shared Research

Since the company’s establishment in 1999, HGF gene therapy drug (a new drug candidate; regenerates blood vessels by medicating HGF—hepatocyte growth factor—genes) has been …See details»

AnGes Inc Company Profile - AnGes Inc Overview - GlobalData

Up-to-date AnGes Inc company overview including funding information, company profile, key statistics, peer comparison and more.See details»

企業調査 - 株式会社フィスコ

で、欧米では販売承認済み。HGPSやPLは遺伝子の突然変異で発症し、症状としては深刻な成長障害、強皮症に似た皮膚、全身性脂肪性筋萎縮症、脱毛症、骨格形成不全、動脈硬化の促進 …See details»

Company AnGes, Inc. Other OTC - MarketScreener.com

AnGes, Inc., formerly AnGes MG, Inc., is a Japan-based company mainly engaged in the development of genetic medicines. The Company is involved in the development of …See details»

日 会社 ¡ アンジェス株式会社 2025 年1 月15日 各 位 会社名 アン …

当社は、2022年9月7日に「改良型 DNA ワクチンの経鼻投与製剤に関する米国スタンフォード大学との共同研究契約の締結について」において公表いたしました共同研究の成果として、新 …See details»

AnGes, Inc. (4563.T) - Yahoo Finance

Find the latest AnGes, Inc. (4563.T) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»

AnGes, Inc. (AnGes, Inc.) - 药物管线_专利_临床试验_投融营收_最新 …

了解AnGes, Inc. (AnGes, Inc.)公司的药物管线,治疗领域,技术平台,以及它的18项临床试验, 25篇新闻和16篇文献,疾病领域:内分泌与代谢疾病,感染,肿瘤,血液及淋巴系统疾病,免 …See details»

EPS Group co-develops COVID-19 vaccine with Osaka University …

EPS Group co-develops COVID-19 vaccine with Osaka University and AnGes Co., Ltd. as a contract research organization EPS Group entered into a development collaboration of DNA …See details»

企業調査 - 株式会社フィスコ

になることを目指している。新薬候補品を開発し、販売パートナーとの販売権許諾契約によって得られる契約一時金や、開発の進捗状況などによって得られるマイルストーン収入、上市後 …See details»

AnGes open for partnership to remain a hero in gene therapy

Feb 3, 2019 “AnGes looks forward to a future of improving human health and quality of life through pioneering in the development of innovative medicines,” says president and CEO Dr …See details»

営業外収益及び営業外 - anges.co.jp

1.営業外収益の計上 1補助金収入 当社と共同開発契約を締結しているカナダのバイオ医薬品企業であるVasomune Therapeutics Inc. が、急性呼吸窮迫症候群(ARDS) を標的とする同社の主 …See details»

linkstock.net © 2022. All rights reserved